Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Medivation, Inc. Shares Tumbled

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Medivation (NASDAQ: MDVN  ) , a biopharmaceutical company focused on developing drugs to treat serious diseases, including cancer, dipped as much as 16% after reporting its fourth-quarter earnings results after the bell last night and issuing fiscal 2014 sales guidance for its lead drug, Xtandi.

So what: For the quarter, Medivation reported $96.6 million collaborative revenue with its partner Astellas Pharma for Xtandi. This includes sales of Xtandi within and outside the U.S., as well as milestone payments received due to predetermined sales markers for advanced prostate cancer treatment Xtandi. Overall, this represented a 160% increase in year-over-year revenue. Medivation was also able to report net income of $2.8 million, or $0.03 per share, compared to a year-ago loss of $31.7 million, or $0.43 per share, in the fourth quarter. Both results absolutely decimated Wall Street's expectation of $72.7 million in revenue and a $0.05 EPS loss. However, the wheels fell off the bus when Medivation issued its full-year sales forecast for Xtandi of $500 million-$535 million, which many investors and analysts found conservative. On the heels of that guidance, Jefferies downgraded Medivation to hold from buy.

Now what: It's not uncommon for biopharma stocks that could be sitting on a blockbuster stock to sandbag the guidance a bit. It's also not a huge surprise to see Medivation shares under pressure considering how much they've run higher over the past year. One thing investors will want to consider, though, is just how impressive its PREVAIL results were in chemotherapy-naive patients last month. The results demonstrated that Xtandi practically ran circles around the placebo in terms of reduced risk of death and radiographic progression and nearly tripled the length of time before patients began chemotherapy. If Xtandi gains this additional pre-chemo indication, which seems likely, it is well on its way to becoming a blockbuster, in my opinion, an excessive weakness from downgrades could be the perfect opportunity needed to buy into this growth if shares continue to fall.

Medivation shares have soared over the past year and may still head higher, but it'll likely be hard-pressed to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2859328, ~/Articles/ArticleHandler.aspx, 9/2/2015 3:10:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,251.12 192.77 1.20%
S&P 500 1,935.17 21.32 1.11%
NASD 4,703.92 67.82 1.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 2:52 PM
MDVN $88.39 Up +2.83 +3.31%
Medivation, Inc. CAPS Rating: ***